CKLIFE SCIENCES (00775) announced that its subsidiary, Sequencio Therapeutics Company Limited, will present a series of research data on the development of therapeutic cancer vaccines at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego. Five research abstracts will highlight preclinical data for investigational vaccines targeting p53 neoantigen, IGF1R (insulin-like growth factor 1 receptor), B7-H3 (B7 homolog 3), TROP2 (trophoblast cell surface antigen 2), and Claudin 6. This marks the first major scientific achievement disclosed by Sequencio Therapeutics since its establishment, demonstrating significant progress in next-generation cancer vaccine technology utilizing its proprietary TrueHLA™ Epitope-to-Efficacy™ translational design framework. This framework enables data-driven vaccine development across circular RNA (circRNA), messenger RNA (mRNA), peptide, and protein technology platforms. Collectively, the presented studies consistently show that rationally designed cancer vaccines elicit strong immunogenicity and significant anti-tumor activity in preclinical models across multiple tumor targets and vaccine constructs. The data confirm Sequencio Therapeutics' capability in translating antigen screening into functional immune responses and tumor control. Based on these results, the company is accelerating IND-enabling studies for its most promising programs and aims to advance selected vaccine candidates into early clinical development through strategic partnerships and global collaboration.